STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
E
Recruiting
- Lymphoma, T-cell, Peripheral
- Lymphoma, T-cell, Cutaneous
- Nagoya, Japan
- +2 more
2021-11-16
Nov 16, 2021C
Recruiting
- Lymphoma, T-Cell, Peripheral
- Osaka, JapanNihon Seimei Hospital
2021-06-01
Jun 1, 2021N
Completed
- Lymphoma, Large-Cell, Anaplasitc
- +4 more
- Anti-CD30-CAR T cells
- +2 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-01-27
Jan 27, 2022F
Recruiting
- Peripheral T-cell Lymphoma
- PD-1 antibody+ HDAC inhibitor
- Shanghai, Shanghai, ChinaDongmei Ji
2021-12-03
Dec 3, 2021P
Not yet recruiting
- T-cell Lymphoma
- Tucidinostat, Azacitidine combined with CHOP
- (no location specified)
2021-10-09
Oct 9, 2021U
Completed
- T-Cell Lymphoma Relapsed
- T-Cell Lymphoma Refractory
- London, United KingdomUniversity College London Hospital
2021-10-01
Oct 1, 2021T
Recruiting
- Relapsed/Refractory Peripheral T-cell Lymphoma
- Anti-PD-1 monoclonal antibody
- +2 more
- Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
2021-12-21
Dec 21, 2021K
Recruiting
- Non Hodgkin Lymphoma (NHL)
- +4 more
- Cincinnati, OhioThe Christ Hospital Cancer Center
2022-02-08
Feb 8, 2022H
Not yet recruiting
- Peripheral T-Cell Lymphoma
- Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
2021-12-26
Dec 26, 2021U
Active, not recruiting
- Peripheral T Cell Lymphoma
- Nivolumab and EPOCH
- Duarte, California
- +2 more
2022-02-03
Feb 3, 2022L
Active, not recruiting
- T-Cell Lymphoma
- +4 more
- LB1901
- Rochester, Minnesota
- +3 more
2022-02-15
Feb 15, 2022D
Recruiting
- Cutaneous T Cell Lymphoma
- Peripheral T Cell Lymphoma
- Microdevices
- +2 more
- Boston, MassachusettsDana Farber Cancer Institute
2021-06-22
Jun 22, 2021N
Recruiting
- Peripheral T-cell Lymphomas
- +2 more
- IOC
- +5 more
- Bethesda, Maryland
- +1 more
2022-04-07
Apr 7, 2022C
Not yet recruiting
- Lymphoma, T-Cell, Peripheral
- Adcetris 50 MG Injection
- +4 more
- Brno, Czechia
- +6 more
2021-08-26
Aug 26, 2021N
Recruiting
- Cutaneous T-Cell Lymphoma
- +3 more
- Romidepsin
- +3 more
- Bethesda, MarylandNational Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022W
Active, not recruiting
- Peripheral T Cell Lymphoma
- Tumor biopsy
- +2 more
- Boston, Massachusetts
- +2 more
2022-02-14
Feb 14, 2022P
Recruiting
- Lymphoma, T-Cell, Cutaneous
- +2 more
- Lenalidomide 15mg
- Brentuximab Vedotin 1.8 mg/Kg
- Melbourne, Victoria, AustraliaPeter MacCallum Cancer Centre
2020-09-29
Sep 29, 2020O
Active, not recruiting
- Relapsed or Refractory Peripheral T-cell Lymphoma(PTCL),Cutaneous T-cell Lymphoma(CTCL),Adult T-cell Leukemia/Lymphoma(ATLL)
- Yamagata, JapanYamagata University Hospital
2022-02-21
Feb 21, 2022T
Active, not recruiting
- Peripheral T Cell Lymphoma
- Pediatric Hodgkin Lymphoma
- Brentuximab Vedotin (Genetical Recombination)
- Tokyo, JapanTakeda Selected Site
2021-09-29
Sep 29, 2021S
Not yet recruiting
- T-cell Lymphoma
- +10 more
- Chicago, IllinoisRush University Medical Center
2021-09-20
Sep 20, 2021U
Recruiting
- Peripheral T Cell Lymphoma
- ATLCAR.CD30 T cells
- +3 more
- Chapel Hill, North Carolina
- +1 more
2022-03-04
Mar 4, 2022K
Completed
- Peripheral T-cell Lymphoma
- Cutaneous T-cell Lymphoma
- KW-0761
- Stanford, CaliforniaStanford University
2020-12-03
Dec 3, 2020U
Terminated
- Lymphoma, T-Cell, Cutaneous
- +6 more
- Ann Arbor, MichiganUniversity of Michigan Rogel Cancer Center
2021-01-20
Jan 20, 2021M
Recruiting
- Peripheral T Cell Lymphoma (PTCL)
- MT-101
- MT-101 + Conditioning (Lymphodepleting) Chemotherapy
- Duarte, California
- +2 more
2022-03-18
Mar 18, 2022R
Active, not recruiting
- Peripheral T Cell Lymphoma
- Ann Arbor, Michigan
- +2 more
2021-08-13
Aug 13, 2021